The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
Sign in to access this content
Sign InXtant Medical Holdings has announced an exclusive U.S. distribution agreement for Dilon Technologies' HEMOBLAST Bellows product. This strategic partnership aims to strengthen the company's position within the global hemostasis market, which is estimated to be worth approximately $2.0 billion. As part of the deal, Xtant has hired Dilon’s specialized U.S. sales team to accelerate market penetration and support commercial growth. The agreement leverages Xtant's robust commercial infrastructure to capture a larger share of the high-value surgical products sector. This move is expected to diversify Xtant's product portfolio and enhance its long-term revenue potential. The collaboration underscores the company's commitment to expanding its advanced medical solution offerings across the United States.